Test Price
7,800 AED✅ Home Collection Available
OncoPro Tumor Mutation Burden (TMB) Test in UAE | 7800 AED | 2026 DHA Guidelines
تحليل OncoPro Tumor Mutation Burden (TMB) في الإمارات | 7800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي: اختبار OncoPro لعبء الطفرات الورمية (TMB) تحليل جينومي متقدم بتقنية التسلسل الجيل التالي (NGS) يحدد عدد الطفرات لكل ميغابيز لتوجيه العلاج المناعي لمرضى السرطان في دولة الإمارات. دقة تشخيصية 99.9% بحساسية فائقة ومعالجة دولية معتمدة بشهادة ISO 9001:2015. نقدم خدمة جمع العينات من المنزل بسلسلة تبريد فائقة الجودة وكادر تمريضي مرخص، مع دعم إكلينيكي هاتفي بعد النتائج. تأكيد التغطية التأمينية يتم عبر واتساب على الرقم +971 54 548 8731.
Overview – Precision Oncology in the UAE
The OncoPro Tumor Mutation Burden (TMB) test is a cutting‑edge next‑generation sequencing assay that quantifies somatic mutations per megabase of tumor DNA, serving as a powerful predictive biomarker for immune checkpoint inhibitor therapy. In the UAE, this DHA‑compliant test uses a single FFPE block, delivers results in 15 working days, and is tailored to empower oncologists, anti‑aging specialists, and bio‑repository managers with genomically‑informed decisions.
يحدد هذا الفحص عدد الطفرات الورمية لكل ميغابيز، مما يساعد الأطباء على تقييم استجابة الورم للعلاج المناعي مثل بيمبروليزوماب ونيفولوماب.
| Feature | Our OncoPro TMB Test | Closest Alternative |
|---|---|---|
| Method | NGS – comprehensive 500+ gene panel | PCR‑based limited gene TMB estimation |
| Precision | 99.9% diagnostic sensitivity; mutation‑level resolution | Moderate; unable to detect rare variants |
| Speed | 15 working days | Often 20+ days |
| Sample | Single FFPE block, ≥10% tumor | May require extra fresh tissue |
Clinical Intent by Specialist Category
- Oncologists: Determine eligibility for pembrolizumab (TMB‑High ≥10 mut/Mb) in metastatic solid tumors and integrate with PD‑L1 status.
- Anti‑Aging Specialists: Assess genomic instability as part of longevity protocols, using TMB as a biomarker of accelerated molecular aging.
- Bio‑repository Managers: Validate FFPE block quality and proceed with high‑value biobanking, ensuring downstream genomic testing reliability.
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA License: 61713011): “This TMB test is an invaluable tool for guiding immunotherapy decisions in appropriate cancer patients. However, it is not a stand‑alone diagnostic and must be interpreted alongside full clinical history, imaging, and other biomarkers. Always maintain a holistic view of the patient’s condition and consult oncology specialists before treatment initiation.”
📌 Medication Safety Notice: Do not discontinue any prescribed medication without explicit advice from your treating physician.
⚠️ Exclusion Criteria & When to Seek Emergency Care
- FFPE block with <10% tumor nuclei – insufficient for reliable TMB calculation.
- Tissue that is severely fragmented or improperly fixed; sample may be rejected.
- Missing histopathology report or NGS requisition form (Form 40) – testing will be deferred.
- ER Red Flags: If the patient experiences acute worsening of symptoms (severe pain, breathing difficulty, bleeding) while awaiting results, seek immediate emergency care – the TMB test is not a substitute for urgent oncology evaluation.
Pre‑Test Information
- Submit a formalin‑fixed paraffin‑embedded (FFPE) block with at least 10% tumor tissue.
- Ship at room temperature; no special cooling needed.
- Attach a copy of the Histopathology report (mandatory).
- Complete and sign the NGS Test Requisition Form (Form 40).
Patient Frequently Asked Questions (FAQ)
1. What is tumor mutation burden and how is it used in cancer treatment?
Tumor mutation burden is the total number of somatic coding mutations per megabase of tumor DNA. In UAE practice, high TMB (≥10 mut/Mb) often predicts better response to immune checkpoint inhibitors such as pembrolizumab, guiding oncologists to select patients most likely to benefit from immunotherapy.
عبء الطفرات الورمية هو عدد الطفرات الجسدية المشفرة لكل ميغابيز من الحمض النووي للورم، ويُستخدم للتنبؤ باستجابة الورم للعلاج المناعي في سرطانات مثل الرئة والميلانوما وأورام الجهاز الهضمي.
2. What are the sample requirements for the OncoPro TMB test?
Only one FFPE tumor block containing at least 10% neoplastic cells, accompanied by a histopathology report. The block is sent at room temperature, and we require a fully completed NGS requisition form (Form 40). No blood draw or fresh tissue is needed.
يلزم توفير كتلة نسيجية مثبتة بالفورمالين ومغمورة بالبارافين (FFPE) تحتوي على 10% خلايا ورمية على الأقل، مع تقرير الأنسجة المرضية ونموذج طلب الفحص الجيني (النموذج 40).
3. How long does it take to get the TMB results in UAE?
Results are reported within 15 working days after sample receipt by Tuesday at 11 am. You will receive a secure, DHA‑compliant report, and our clinical team offers telephonic guidance to help with interpretation.
تصدر النتائج خلال 15 يوم عمل بعد استلام العينة يوم الثلاثاء الساعة 11 صباحاً، مع توفير استشارة هاتفية لتفسير التقرير من قبل فريق سريري معتمد.
UAE Regulatory & Data Privacy Compliance
- Tests are performed under MOHAP Laboratory License No. 9834453 and align with Federal Decree‑Law No. 41 of 2024 (Art. 87) on medical advertising.
- For patients under 18, the UAE CDS Law 2026 ensures guardian consent and strict data handling.
- Personal health data is protected under UAE PDPL (Federal Decree‑Law No. 45 of 2021) and never shared without explicit patient consent.
- ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) guarantees quality management across all pre‑analytical and analytical phases.
Direct Insurance Billing Verification & Appointment: WhatsApp +971 54 548 8731 (available 8 AM – 11 PM daily).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians